SG Americas Securities
OTLK icon

SG Americas Securities’s Outlook Therapeutics OTLK Stock Holding History

SG Americas Securities’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,876
Closed -$15K – 3307
2023
Q4 		$15K Buy
1,876
+876
+88% +$7.41K ﹤0.01% 3021
2023
Q3 		$4K Buy
+1,000
New +$22.1K ﹤0.01% 3074
2023
Q2 		– Sell
-3,097
Closed -$68K – 2939
2023
Q1 		$68K Buy
+3,097
New +$69.3K ﹤0.01% 3016
2022
Q4 		– Sell
-1,246
Closed -$30K – 3299
2022
Q3 		$30K Buy
1,246
+361
+41% +$8.39K ﹤0.01% 3061
2022
Q2 		$18K Buy
+885
New +$25.4K ﹤0.01% 3345
2022
Q1 		– Sell
-1,262
Closed -$34K – 3316
2021
Q4 		$34K Sell
1,262
-979
-44% -$34.9K ﹤0.01% 3225
2021
Q3 		$97K Buy
+2,241
New +$108K ﹤0.01% 3671

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

SG Americas Securities's OTLK Position: Q1 2024 in Review

SG Americas Securities sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 1,876 shares — an estimated $15K sold.

SG Americas Securities first reported a position in OTLK in Q3 2021 and held it in 7 quarters. The position peaked at $97K in Q3 2021. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • SG Americas Securities reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • SG Americas Securities sold 1,876 Outlook Therapeutics shares in Q1 2024, an estimated $15K.
  • SG Americas Securities first reported a position in Outlook Therapeutics in Q3 2021 and held it in 7 quarters.
  • SG Americas Securities's Outlook Therapeutics position peaked at $97K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on SG Americas Securities's 13F filing for Q1 2024, filed 6 May 2024.